What Is Oncology

Oncology is the branch of medicine devoted to the diagnosis, treatment, and monitoring of cancer across all organ systems and age groups. The field sits at the intersection of molecular biology, clinical pharmacology, surgery, and radiation physics, making it one of the most technically diverse disciplines in modern medicine. Understanding its scope and internal structure is essential for patients, referring physicians, and anyone navigating a cancer diagnosis or cancer screening guidelines.

Definition and Scope

Cancer — the uncontrolled proliferation and potential metastasis of abnormal cells — is diagnosed in approximately 1.9 million Americans per year, according to the National Cancer Institute (NCI) SEER Program. Oncology addresses every stage of that disease arc: risk stratification, early detection, pathological confirmation, treatment planning, response monitoring, survivorship, and end-of-life care.

The discipline is formally organized into three primary branches:

  1. Medical oncology — systemic therapies including chemotherapy, immunotherapy, targeted therapy, and hormone therapy administered by a board-certified medical oncologist.
  2. Surgical oncology — the operative removal of tumors and adjacent tissue, including sentinel lymph node procedures and cytoreductive surgery.
  3. Radiation oncology — the use of ionizing radiation to destroy or shrink tumors, delivered via external beam or brachytherapy techniques.

Beyond these three pillars, oncology encompasses more than 20 recognized subspecialties catalogued by the American Board of Internal Medicine (ABIM) and the American Board of Medical Specialties (ABMS), including hematology-oncology, gynecologic oncology, pediatric oncology, and neuro-oncology. The full landscape of these divisions is mapped in subspecialties of oncology.

Regulatory oversight of oncology practice in the United States is distributed across multiple federal agencies. The U.S. Food and Drug Administration (FDA) governs oncology drug approval under 21 CFR Parts 312 and 314, including the accelerated approval pathway established under 21 CFR §314.500. The Centers for Medicare & Medicaid Services (CMS) regulates reimbursement for oncology services through its Oncology Care Model and Merit-based Incentive Payment System (MIPS). A detailed treatment of agency jurisdiction appears at regulatory context for oncology.

How It Works

Oncology practice follows a structured diagnostic-to-treatment pipeline that the NCI and major cooperative groups such as the Eastern Cooperative Oncology Group (ECOG) have formalized through clinical trial protocols and performance status scales.

The clinical pathway proceeds through discrete phases:

  1. Suspicion and referral — A primary care provider or specialist identifies symptoms, abnormal imaging, or elevated tumor markers and refers to oncology.
  2. Pathological confirmation — Tissue biopsy remains the diagnostic gold standard. Pathologists classify tumors by histological type, grade, and, increasingly, molecular profile (molecular profiling and biomarkers).
  3. Staging — The American Joint Committee on Cancer (AJCC) TNM staging system, published in the AJCC Cancer Staging Manual (8th edition, 2017), classifies tumors by primary Tumor size (T), lymph Node involvement (N), and distant Metastasis (M). Stages run from I (localized) through IV (distant spread).
  4. Multidisciplinary tumor board review — Major cancer centers convene oncologists, surgeons, radiologists, pathologists, and radiation oncologists to reach a consensus treatment plan, a practice supported by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.
  5. Treatment execution and response monitoring — Systemic therapy, radiation, surgery, or combination protocols are delivered with periodic imaging and laboratory reassessment.
  6. Survivorship and surveillance — Post-treatment follow-up protocols track recurrence and manage late effects, as outlined in NCCN Survivorship Guidelines.

The molecular revolution has fundamentally altered step 3 and step 5. Next-generation sequencing (NGS) panels now identify actionable mutations — such as EGFR exon 19 deletions in non-small cell lung cancer or BRCA1/2 alterations in breast and ovarian cancers — that determine eligibility for specific targeted agents. The FDA's list of approved companion diagnostics, maintained at fda.gov/medical-devices, links 40+ diagnostic assays directly to matched therapies as of the most recent agency publication.

Common Scenarios

Oncology encounters cluster around a defined set of high-incidence diagnoses. The five most frequently diagnosed cancers in the United States by incidence, per NCI SEER data, are:

Each cancer type routes through a distinct diagnostic and treatment pathway. Lung cancer workup typically requires low-dose CT imaging per the United States Preventive Services Task Force (USPSTF) Grade B recommendation for high-risk adults aged 50–80, while colorectal cancer screening employs colonoscopy or stool-based tests on separate USPSTF-endorsed schedules.

Oncology also addresses patients who present not with a new diagnosis but with an abnormal screening result, a hereditary risk flag from genetic testing, or a request for a second opinion on a cancer diagnosis. These scenarios involve risk communication and shared decision-making frameworks standardized by professional bodies including the American Society of Clinical Oncology (ASCO).

Decision Boundaries

Oncology's scope is broad, but it has defined decision boundaries — points at which the specialty hands off to or draws in other disciplines.

Oncology vs. general medicine: A general internist manages cancer survivors on stable surveillance protocols, but active treatment decisions, recurrence workups, and modification of systemic therapy protocols fall within the oncologist's domain.

Medical oncology vs. surgical oncology: The determination of surgical candidacy depends on tumor resectability, patient performance status (commonly measured on the 0–4 ECOG scale), and the anticipated benefit-to-risk ratio. A medically unresectable tumor shifts the treatment axis toward radiation or systemic therapy. The contrast between these two modalities is detailed in surgical oncology and radiation therapy.

Curative vs. palliative intent: This is the most consequential decision boundary in oncology. When curative intent is not clinically feasible — typically at Stage IV for solid tumors without an approved targeted agent — care pivots toward palliative care with goals focused on symptom control and quality of life rather than tumor eradication. ASCO's integration guidelines recommend introducing palliative care alongside active treatment at diagnosis for patients with advanced solid tumors, a standard that reduces unnecessary aggressive intervention.

Oncology vs. clinical trial eligibility: When standard-of-care options have been exhausted or when a tumor harbors a targetable alteration without an approved agent, referral to clinical trials becomes the operative decision. The FDA's Expanded Access program (21 CFR Part 312, Subpart I) and the NCI's Cancer Therapy Evaluation Program (CTEP) govern eligibility and safety monitoring in this boundary zone.

The broader overview of oncology's place in American medicine — including how the field interfaces with the oncologyauthority.com resource index — reflects a system in which a cancer diagnosis no longer follows a single linear pathway but branches at each stage according to histology, molecular profile, patient fitness, and institutional resources.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)